Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Melo

Showing results (21-30 of 330) with videos related to

Pageof 33
Sort By:
Nature Reviews. Cancer|May 25, 2007
Chronic myeloid leukaemia as a model of disease evolution in human cancerJunia V Melo, David J Barnes
Acta Haematologica|June 21, 2008
BCR-ABL in chronic myelogenous leukemia--how does it work?John M Goldman, Junia V Melo
The New England Journal of Medicine|April 5, 2001
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemiaJ M Goldman, J V Melo
Seminars in Hematology|June 5, 2003
Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studiesAlex J Tipping, Junia V Melo
Seminars in Hematology|February 4, 2003
Management of chronic myeloid leukemia: targets for molecular therapyDavid J Barnes, Junia V Melo
The New England Journal of Medicine|October 10, 2003
Chronic myeloid leukemia--advances in biology and new approaches to treatmentJohn M Goldman, Junia V Melo
Hematology. American Society of Hematology. Education Program|December 14, 2011
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?Junia V Melo, David M Ross
Best Practice & Research. Clinical Haematology|August 25, 2009
The impact of gene profiling in chronic myeloid leukaemiaAgnes S M Yong, Junia V Melo
Hematology/Oncology Clinics of North America|July 24, 2004
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformationJunia V Melo, Michael W N Deininger
Journal of Clinical Pathology|May 1, 1987
Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10)S Haralambidou, J V Melo, D Catovsky
Pageof 33

Showing results (21-30 of 330) with videos related to

Sort By:
Pageof 33
Nature Reviews. Cancer|May 25, 2007
Chronic myeloid leukaemia as a model of disease evolution in human cancerJunia V Melo, David J Barnes
Acta Haematologica|June 21, 2008
BCR-ABL in chronic myelogenous leukemia--how does it work?John M Goldman, Junia V Melo
The New England Journal of Medicine|April 5, 2001
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemiaJ M Goldman, J V Melo
Seminars in Hematology|June 5, 2003
Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studiesAlex J Tipping, Junia V Melo
Seminars in Hematology|February 4, 2003
Management of chronic myeloid leukemia: targets for molecular therapyDavid J Barnes, Junia V Melo
The New England Journal of Medicine|October 10, 2003
Chronic myeloid leukemia--advances in biology and new approaches to treatmentJohn M Goldman, Junia V Melo
Hematology. American Society of Hematology. Education Program|December 14, 2011
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?Junia V Melo, David M Ross
Best Practice & Research. Clinical Haematology|August 25, 2009
The impact of gene profiling in chronic myeloid leukaemiaAgnes S M Yong, Junia V Melo
Hematology/Oncology Clinics of North America|July 24, 2004
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformationJunia V Melo, Michael W N Deininger
Journal of Clinical Pathology|May 1, 1987
Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10)S Haralambidou, J V Melo, D Catovsky
Pageof 33